<u>!</u>			
	Application No.	Applicant(s)	
Nation of Allowability	10/670,009	COSGROVE ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Tekchand Saidha	1652	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. This communication is responsive to <i>November 16 2006</i> .			
2. The allowed claim(s) is/are 1.4 and 12.			
<ul> <li>3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> </ul>			
1. Certified copies of the priority documents have been received.			
2. Certified copies of the priority documents have been received in Application No			
3.  Copies of the certified copies of the priority documents have been received in this national stage application from the			
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.			
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.			
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached			
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).			
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
Attachment(s)			
1. Notice of References Cited (PTO-892)	5. Notice of Informal Pa	atent Application	
2.  Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary		
3 M Information Disclosure Statements (PTO/SR/08)	Paper No./Mail Date 7.  Examiner's Amendm		
3. A Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 9/24/03 (Proviously Consider	end ) " \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	enocomment	
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Statement	nt of Reasons for Allowance	,
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material  Corrections added to 2 references	9. 🗆 Other		

Application/Control Number: 10/670,009

Art Unit: 1652

## Notice of Allowability

- 1. The terminal disclaimer filed on November 16 2006 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US Patents 6,255,466 has been reviewed and is accepted. The terminal disclaimer has been recorded.
- 2. Applicants' response to Final rejection filed on November 2 2006 acknowledged. In view of claim amendments and the filing of the terminal disclaimer all prior rejections are hereby withdrawn.
- 3. Claims 1, 4 & 12 are present and under consideration in this application.
- 4. Claims 1, 4 & 12 are allowed, subject to the following Examiner's Amendment.
- 5. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Janae Lehman-Bell on January 6, 2006.

## Amend claim 12 as follows:

Claim 12, line 1, after 'An isolated nucleic acid sequence', insert 'of claim 1'.

5. The following is an examiner's statement of reasons for allowance:

This Application provides an isolated polynucleotide encoding a protein having expansin activity wherein said polynucleotide hybridizes under defined high stringency conditions to the sequence of SEQ ID NO: 1.

Page 3

Application/Control Number: 10/670,009

Art Unit: 1652

No prior art reference or sequence of record, however, taken alone or in combination teach the claimed invention or provide motivation to one of ordinary skill in the art to use the skills available in the area of enzymology or molecular biology, to make the invention obvious.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tekchand Saidha whose telephone number is (571) 272 0940. The examiner can normally be reached on 8.30 am - 5.00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on (571) 272 0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Tekchand Saidha

Primary Examiner, Art Unit 1652

Recombinant Enzymes, 02A65 Remsen Bld.

400 Dulany Street, Alexandria, VA 22314

Telephone: (571) 272-0940

January 8, 2007